About Ivanovo Regional Oncology Dispensary
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
15
Janssen Research & Development, LLC
6
Incyte Corporation
3
Bayer
2
BeiGene
1
Bristol-Myers Squibb
1
Genentech, Inc.
1
Hinova Pharmaceuticals USA, Inc.
1
Janssen Pharmaceutica N.V., Belgium
1
Jiangsu HengRui Medicine Co., Ltd.
1
Clinical Trials at Ivanovo Regional Oncology Dispensary
During the past decade, Ivanovo Regional Oncology Dispensary conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 13 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 4 clinical trials were completed. i.e. 40%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
2008-02-12
2018-11-23
Completed
808
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
2009-10-16
2017-01-24
Completed
596
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
2010-07-31
2016-09-16
Completed
1,095
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
2012-09-03
2016-04-30
Terminated
415
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
2012-12-03
2017-05-31
Terminated
182
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
2014-01-31
2021-06-04
Completed
1,846
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
2015-04-09
2021-06-29
Terminated
631
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
2015-06-23
2021-08-31
Completed
902
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Ivanovo Regional Oncology Dispensary" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Janssen Research & Development, LLC" with 6 trials
sponsored, "Incyte Corporation" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "BeiGene"
with 2 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Ivanovo Regional Oncology Dispensary"
#1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 8 trials.
Clinical Trials Conditions at Ivanovo Regional Oncology Dispensary
According to Clinical.Site data, the most researched conditions in "Ivanovo Regional Oncology Dispensary" are
"Breast Cancer" (6 trials), "Early Breast Cancer" (2 trials), "Gastric Cancer" (2 trials), "Prostatic Neoplasms" (2 trials) and "Triple Negative Breast Cancer" (2 trials). Many other conditions were trialed in "Ivanovo Regional Oncology Dispensary" in a lesser frequency.
Clinical Trials Intervention Types at Ivanovo Regional Oncology Dispensary
Most popular intervention types in "Ivanovo Regional Oncology Dispensary" are "Drug" (30 trials), "Other" (4 trials), "Radiation" (3 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (11 trials), "Docetaxel" (5 trials), "Paclitaxel" (5 trials), "Atezolizumab" (4 trials) and "Cisplatin" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Ivanovo Regional Oncology Dispensary
The vast majority of trials in "Ivanovo Regional Oncology Dispensary" are
22 trials for "All" genders, 8 trials for "Male" genders and 2 trials for "Female" genders.
Clinical Trials Status at Ivanovo Regional Oncology Dispensary
Currently, there are NaN active trials in "Ivanovo Regional Oncology Dispensary".
undefined are not yet recruiting,
9 are recruiting,
9 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 11 completed trials in Ivanovo Regional Oncology Dispensary,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Ivanovo Regional Oncology Dispensary, 1 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 29 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".